The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, ...
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit ...
U.S.-based Vertex Pharmaceuticals (VRTX) has secured approval from the FDA (Food and Drug Administration) for its ...
Vertex Pharmaceuticals on Thursday won approval from the Food and Drug Administration for a non-opioid pain drug, clearing ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...